Julie Papanek

Julie Papanek

Julie Papanek is a healthcare VC at Canaan Partners, a tech and healthcare fund currently investing its 10th fund of $650M. She leads early stage investments in novel biopharmaceutical and digital health companies.

LinkedIn: https://www.linkedin.com/in/julie-papanek-a8961b1
Twitter: https://twitter.com/juliepapanek
San Francisco, California, United States
Accredited investor
Member since January 30, 2016
I'm a healthcare VC at Canaan Partners and lead early stage pharmaceutical, biotech and digital health investments. Quote_down
  • About
Investor interests
Type of investor Early stage VC
Typical investment size More than $2.5M
Typical investments in a year 2
Categories of interest
Locations of interest
Credentials Accredited Investor
Investments made Protagonist Therapeutics
Board seats Protagonist Therapeutics, Labrys, Glooko
2005 Yale University , BS , Biophysics and Biochemistry
2006 Cambridge University , MS , Biotechnology
2013 Stanford University , MBA

Companies I work or worked for:
Genentech, Canaan Partners, Proteus Digital Health, Narayana Hrudayalaya
Full bio

Julie Papanek is a healthcare VC at Canaan Partners who brings operational experience from biotechnology and digital health. Prior to Canaan, Julie worked at Genentech in a variety of positions spanning marketing, development, and business development. Julie holds an MBA from Stanford’s Graduate School of Business and earned an MPhil from Cambridge University in BioScience Enterprise and a B.S. from Yale University in Molecular Biophysics and Biochemistry. She is a director at Protagonist Therapeutics and played an active role in Canaan's previous investments in CytomX, Labrys, Glooko, Chrono, Truveris, Aldea Pharmaceuticals, Cellular Research and Dermira. 

Within the life sciences, Julie is focused on pre-clinical and early clincial biopharmaceutical companies pursuing novel platforms or biology. Within digital health, Julie has a particular interest in tech companies creating products for the life science sector, consumer affordability, revenue cycle management, and b2b financial products.